Short answer
Kyverna Therapeutics Inc (KYTX) filed an 8-K current report with the SEC on August 11, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Kyverna reported financial results for the quarter ended June 30, 2026.
Kyverna Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Kyverna reported financial results for the quarter ended June 30, 2026
- Business update and quarterly results available in Exhibit 99.1, relevant for pipeline and liquidity assessment
Item EX-99.1 · Exhibit EX-99.1
- RMAT designation for miv-cel in non-active SPMS expands regulatory pathways and supports a broader neuroimmunology franchise
- Rolling SPS BLA submission on track for Q4 2026, with potential priority review and 2027 commercial launch
- Q2 net loss $38.3M, or $0.63 per share, versus $42.1M, or $0.97 per share, in Q2 2025
- Cash, equivalents and marketable securities $199.4M at June 30, 2026, supporting operating runway into 2028 alongside loan availability
- Key catalysts: KYSA-8 12-month data and gMG Phase 2 follow-up in Q3 2026, PMS data in Q4 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kyverna Therapeutics Inc 8-K filings
Get the next KYTX 8-K as it lands
Follow KYTX for push alerts, or ask the research agent what this filing means.